alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Home › Research › Topic

Plasma and spinal-fluid biomarkers

1,573 studies in this group. A computer grouped them by what their titles and summaries are about, not by a hand-made list. The name describes most of the group, not every study in it.

Each study has a usefulness score out of 100 (rubric version 4.0). Tap a score to see what makes it up.

Highest usefulness score first. Studies without a score come last.

  1. Cerebrospinal Fluid Profile of Lipid Mediators in Alzheimer's Disease

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. Cellular and molecular neurobiology 2022-04-01 Tau biomarkers

    Alzheimer's disease (AD) develops into dementia over a period of several years, during which subjective cognitive impairment (SCI) and mild cognitive impairment (MCI) can be used as intermediary diagnoses of increasing severity.

  2. Overview of tau PET molecular imaging

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. Current opinion in neurology 2022-04-01 Brain scans and imaging

    This article reviews tau PET imaging with an emphasis on first-generation and second-generation tau radiotracers and their application in neurodegenerative disorders, including Alzheimer's disease and non-Alzheimer's disease tauopathies.

  3. CSF biomarkers for dementia

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. Practical neurology 2022-03-17 Biomarkers

    Although cerebrospinal fluid (CSF) biomarker testing is incorporated into some current guidelines for the diagnosis of dementia (such as England's National Institute for Health and Care Excellence (NICE)), it is not widely accessible for most patients for whom biomarkers could potentially change management.

  4. Decreased imaging time of amyloid PET using [18F]florbetapir can maintain quantitative accuracy

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. Radiological physics and technology 2022-03-03 Brain scans and imaging

    Shortening the amount of time required to acquire amyloid positron emission tomography (PET) brain images while maintaining the accuracy of quantitative evaluation would help to overcome motion artifacts associated with Alzheimer's disease patients.

  5. Tau-PET imaging predicts cognitive decline and brain atrophy progression in early Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. Journal of neurology, neurosurgery, and psychiatry 2022-02-28 Brain scans and imaging

    Baseline tau-PET was strongly associated with the subsequent cognitive decline in regions that are usually associated with each cognitive domain.

  6. Alzheimer's Disease Seen through the Eye: Ocular Alterations and Neurodegeneration

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. International journal of molecular sciences 2022-02-24 Brain scans and imaging

    Alzheimer's Disease (AD) is one of the main neurodegenerative diseases worldwide.

  7. Software development for quantitative analysis of brain amyloid PET

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. Brain and behavior 2022-02-08 Brain scans and imaging

    When whole cerebellum or whole cerebellum plus brainstem was chosen as the reference area, an excellent correlation was found between the CL scale calculated by this software and the CL scale published by GAAIN.

  8. International consensus on the use of tau PET imaging agent 18F-flortaucipir in Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. European journal of nuclear medicine and molecular imaging 2022-01-03 Brain scans and imaging

    This international consensus and practice guideline will help to promote the standardized use of 18F-flortaucipir PET in patients with AD.

  9. Plasma Neurofilament Light Chain and Clinical Diagnosis in Frontotemporal Dementia Syndromes

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. Journal of Alzheimer's disease : JAD 2022 Biomarkers

    Fifty participants were studied: bvFTD = 20, semantic variant FTD (svFTD) = 11, non-fluent variant FTD (nfvFTD) = 9, FTD with motor neuron disease (MND) = 4, phFTD = 2, slow progressors = 3, FTD mimic = 1, mean age 67.2 (SD 8.4) years.

  10. A Review of Application of Aβ42/40 Ratio in Diagnosis and Prognosis of Alzheimer's Disease

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. Journal of Alzheimer's disease : JAD 2022 Biomarkers

    The number of patients with Alzheimer's disease (AD) and non-Alzheimer's disease (non-AD) has drastically increased over recent decades.

  11. Blood Tests for Alzheimer's Disease: Increasing Efforts to Expand and Diversify Research Participation Is Critical for Widespread Validation and Acceptance

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. Journal of Alzheimer's disease : JAD 2022 Biomarkers

    The recent academic and commercial development, and regulatory approvals, of blood-based Alzheimer's disease (AD) biomarkers are breakthrough developments of immense potential.

  12. A Blood Test for Alzheimer's Disease: It's about Time or Not Ready for Prime Time?

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. Journal of Alzheimer's disease : JAD 2022 Biomarkers

    A blood test for Alzheimer's disease is now available for clinical use in persons with cognitive impairment.

  13. Retinal Examinations Provides Early Warning of Alzheimer's Disease

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. Journal of Alzheimer's disease : JAD 2022 Brain scans and imaging

    Patients with Alzheimer's disease have difficulty maintaining independent living abilities as the disease progresses, causing an increased burden of care on family caregivers and the healthcare system and related financial strain.

  14. Cerebrospinal Fluid Biomarkers for Cerebral Amyloid Angiopathy Diagnosis

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. Journal of Alzheimer's disease : JAD 2022 Vascular contributions

    An accurate diagnosis of sporadic cerebral amyloid angiopathy (CAA) is critical for patient management and research (including clinical trials) for this common small vessel pathology of the brain.

  15. Patterns of Mixed Pathologies in Down Syndrome

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. Journal of Alzheimer's disease : JAD 2022 Brain tissue and pathology

    Tau and amyloid-β pathology was prevalent in all cases and compatible with that typically seen in AD with some subtle deviations.

  16. Distributions of Aβ42 and Aβ42/40 in the Cerebrospinal Fluid in View of the Probability Theory

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. Diagnostics (Basel, Switzerland) 2021-12-16 Biomarkers

    Amyloid β 42/40 concentration quotient has been empirically shown to improve accuracy of the neurochemical diagnostics of Alzheimer's Disease (AD) compared to the Aβ42 concentration alone, but this improvement in diagnostic performance has not been backed up by a theoretical argumentation so far.

  17. 4D flow MRI hemodynamic biomarkers for cerebrovascular diseases

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. Journal of internal medicine 2021-11-23 Vascular contributions

    Alterations in cerebral blood flow are common in several neurological diseases among the elderly including stroke, cerebral small vessel disease, vascular dementia, and Alzheimer's disease. 4D flow magnetic resonance imaging (MRI) is a relatively new technique to investigate cerebrovascular disease, and makes it possible to obtain time-resolved blood flow measurements of the entire cerebral arterial venous vasculature and can be used to derive a repertoire of hemodynamic biomarkers indicative of cerebrovascular health.

  18. Retinal imaging biomarkers of neurodegenerative diseases

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. Clinical & experimental optometry 2021-11-09 Brain scans and imaging

    The timely detection of neurodegenerative diseases is central to improving clinical care as well as enabling the development and deployment of disease-modifying therapies.

  19. P-tau235: a novel biomarker for staging preclinical Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. EMBO molecular medicine 2021-11-02 Biomarkers

    Alzheimer's disease (AD) is characterised by a long preclinical phase.

  20. Cerebrospinal fluid dynamics and discordant amyloid biomarkers

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. Neurobiology of aging 2021-11-01 Tau biomarkers

    Do MRI-based metrics of a CSF-dynamics disorder, disproportionately enlarged subarachnoid-space hydrocephalus (DESH), correlate with discordant amyloid biomarkers (low CSF β-amyloid 1-42, normal Aβ-PET scan)?

  21. [Retinal Imaging as Potential Biomarkers for Dementia]

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. Brain and nerve = Shinkei kenkyu no shinpo 2021-11 Brain scans and imaging

    Alzheimer's disease (AD) is a leading cause of dementia, and the current diagnostic methods of AD, such as positron emission tomography imaging, have a high cost and poor accessibility.

  22. Ophthalmic manifestations of dementing disorders

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. Current opinion in ophthalmology 2021-11-01 Brain scans and imaging

    Dementia is a term for loss of memory, language, problem-solving, and other thinking abilities, which significantly interferes with daily life.

  23. Plasma neurofilament L to amyloid β42 ratio in differentiating Alzheimer's type from non-Alzheimer's dementia: A cross-sectional pilot study from India

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. Asian journal of psychiatry 2021-10-29 Biomarkers

    Based on the reduction of amyloid β plaques, US FDA has recently approved Aducanumab as a disease modifying treatment for Alzheimer's disease (AD).

  24. Neurogranin and Neuronal Pentraxin Receptor as Synaptic Dysfunction Biomarkers in Alzheimer's Disease

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. Journal of clinical medicine 2021-10-02 Disease mechanisms

    The CSF level of Ng was significantly higher, whereas the NPTXR was significantly lower in the AD patients than in cognitively healthy controls.

  25. Detection of Cerebrospinal Fluid Neurofilament Light Chain as a Marker for Alpha-Synucleinopathies

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. Frontiers in aging neuroscience 2021-09-22 Biomarkers

    Alpha-synucleinopathies, such as Parkinson's disease (PD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA), are a class of neurodegenerative diseases.

From across this topic

10 of the 1,573 studies in this topic, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.

Other topics